Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1106 in Solid Tumors and Urothelial Carcinoma
NCT07416123Phase 1Recruiting
- Sponsor
- Genmab
- Start
- Apr 2026
- Primary completion
- Apr 2029
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of GEN1106 in solid tumor and urothelial carcinoma (UC) (3 arms), sponsored by Genmab. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Events and Serious Adverse Events at 16 months and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
GEN1106
03
Conditions
solid tumorurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07416123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07416123.